• Publications
  • Influence
A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation.
TLDR
The risk of CIN after PCI can be simply assessed using readily available information and can be used for both clinical and investigational purposes. Expand
A prospective natural-history study of coronary atherosclerosis.
TLDR
In patients who presented with an acute coronary syndrome and underwent percutaneous coronary intervention, major adverse cardiovascular events occurring during follow-up were equally attributable to recurrence at the site of culprit lesions and to nonculprit lesions. Expand
Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis
TLDR
A network meta-analysis with a mixed-treatment comparison method to combine direct within-trial comparisons between stents with indirect evidence from other trials while maintaining randomisation found sirolimus-eluting stents seem to be clinically better than bare-metal and paclitaxel-eluted stents. Expand
Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.
TLDR
Overall, the superiority of primary PCI over thrombolysis seems to be especially clinically relevant for the time interval between 3 and 12 h after onset of chest pain or other symptoms on the basis of its superior preservation of myocardium. Expand
Bivalirudin during primary PCI in acute myocardial infarction.
TLDR
In patients with ST-segment elevation myocardial infarction who are undergoing primary PCI, anticoagulation with bivalirudin alone, as compared with heparin plus glycoprotein IIb/IIIa inhibitors, results in significantly reduced 30-day rates of major bleeding and net adverse clinical events. Expand
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
TLDR
Stent thrombosis after 1 year was more common with both sirolimus-eluting stents and paclitaxel-eluted stents than with bare-metal stents, and both drug-elution stents were associated with a marked reduction in target-lesion revascularization. Expand
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
TLDR
The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed. Expand
Extrapulmonary manifestations of COVID-19
TLDR
The extrapulmonary organ-specific pathophysiology, presentations and management considerations for patients with COVID-19 are reviewed to aid clinicians and scientists in recognizing and monitoring the spectrum of manifestations, and in developing research priorities and therapeutic strategies for all organ systems involved. Expand
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
TLDR
Stent implantation (with or without abciximab therapy) should be considered the routine reperfusion strategy in experienced centers and when used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further improve outcomes. Expand
...
1
2
3
4
5
...